Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Irreversible Inactivation of the Opiate Receptors in the Neuroblastoma x Glioma Hybrid NG108-15 by Chlornaltrexamine

ROBERT FANTOZZI, DEBRA MULLIKIN-KILPATRICK and ARTHUR J. BLUME
Molecular Pharmacology July 1981, 20 (1) 8-15;
ROBERT FANTOZZI
Department of Physiological Chemistry and Pharmacology, Roche Institute of Molecular Biology, Nutley, New Jersey 07110
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DEBRA MULLIKIN-KILPATRICK
Department of Physiological Chemistry and Pharmacology, Roche Institute of Molecular Biology, Nutley, New Jersey 07110
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ARTHUR J. BLUME
Department of Physiological Chemistry and Pharmacology, Roche Institute of Molecular Biology, Nutley, New Jersey 07110
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Chlornaltrexamine irreversibly inactivates opiate receptors in intact NG108-15 cells in a concentration- and time-dependent fashion. This inactivation is seen as a loss in the number of receptors per cell (decrease in Bmax), and is quantitatively the same whether based on the number of specific binding sites for the agonist opioid peptide [D-Ala2-Met5] enkephalinamide or those for the opiate antagonist naltrexone. Inactivation appears to require direct interaction of chlornaltrexamine with these receptors as naltrexone and [D-Ala2-Met5]enkephalinamide protect against the irreversible effects of chlornaltrexamine. Furthermore, treatment with chlornaltrexamine does not decrease muscarinic or prostaglandin receptors or diazepam binding sites in NG108-15. In intact NG108-15 cells, the opioid peptide [D-Ala2-Met5]enkephalinamide can inhibit 80 ± 10% of the accumulation of cyclic AMP that is stimulated by prostaglandin E1. In control cells, the action of this peptide is cooperative and the half-maximum effect (Kinh) occurs with 3.3 nM peptide. Under identical conditions, the half-maximum receptor occupancy by the peptide (KD) is 23 nM. After the opiate receptor number is significantly decreased by previous incubation with chlornaltrexamine, both the maximal effects of prostaglandin E1, as stimulator of cyclic AMP accumulation, and the opioid peptide, as inhibitor of this accumulation, are maintained. In the case where the receptor number has been reduced by 95%, although there is a small change (≤3-fold) in the KD and Kinh values for this opioid peptide, there is no significant change in the KD/Kinh ratio which remains ≃7. These results indicate that the high density of opiate receptors which exist in intact NG108-15 cells is not necessary for the maximum inhibitory effect of this enkephalinamide on adenylate cyclase. In addition, the mode of action of this peptide also appears to be relatively independent of the density of the opiate receptors in these cells.

  • Copyright © 1981 by The American Society for Pharmacology and Experimental Therapeutics

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology
Vol. 20, Issue 1
1 Jul 1981
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Irreversible Inactivation of the Opiate Receptors in the Neuroblastoma x Glioma Hybrid NG108-15 by Chlornaltrexamine
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Irreversible Inactivation of the Opiate Receptors in the Neuroblastoma x Glioma Hybrid NG108-15 by Chlornaltrexamine

ROBERT FANTOZZI, DEBRA MULLIKIN-KILPATRICK and ARTHUR J. BLUME
Molecular Pharmacology July 1, 1981, 20 (1) 8-15;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Irreversible Inactivation of the Opiate Receptors in the Neuroblastoma x Glioma Hybrid NG108-15 by Chlornaltrexamine

ROBERT FANTOZZI, DEBRA MULLIKIN-KILPATRICK and ARTHUR J. BLUME
Molecular Pharmacology July 1, 1981, 20 (1) 8-15;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Michaelis Menten quantification of GPCR-G protein signalling
  • Human mAb 3F1 targeting the fuctional epitopes of Siglec-15
  • The regulation and mechanisms of ImKTX58 on KV1.3 channel
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics